Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease

20Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rheumatic fever (RF) and rheumatic heart disease (RHD) are postinfectious complications of an infection (or repeated infection) with the Gram-positive bacterium, Streptococcus pyogenes (also known as group A streptococcus, GAS). RF and RHD are global problems and affect many indigenous populations of developed countries and many developing countries. However, RF and RHD are only part of a larger spectrum of diseases caused by this organism. The development of a vaccine against GAS has primarily targeted the abundant cell-surface protein called the M-protein. This review focuses on different M-protein-based-subunit vaccine approaches and the different delivery technologies used to administer these vaccine candidates in preclinical studies. © 2006 Humana Press Inc.

Cite

CITATION STYLE

APA

Batzloff, M. R., Pandey, M., Olive, C., & Good, M. F. (2006, July). Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunologic Research. https://doi.org/10.1385/IR:35:3:233

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free